Chutes & Ladders—FDA nod for Biogen's Aduhelm sees trio of AdComm members hit the exit
Ogilvy and McCann heavyweight Andrew Schirmer has joined Syneos Health's GSW New York as president. Three members of the FDA panel that argued against aducanumab have quit in the wake of the Alzheimer's drug's approval. Inogen, recently equipped with a new CEO, has tapped BD vet Stanislav Glezer, M.D., as its chief medical officer.
Source: fiercebiotech.com